Efocipegtrutide
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Efocipegtrutide (HM15211) is a triple agonist of the glucagon, GIP, and glucagon-like peptide 1 receptors. It is being studied for obesity and nonalcoholic steatohepatitis.[1][2][3]
| Clinical data | |
|---|---|
| Other names | HM15211 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| ChEMBL | |
